Drugs / ORM-5029
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05511844 | Oct 2022 → Jun 2025 | HER2 positive breast carcinoma | Orum Therapeutics USA, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORM-5029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05511844 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05511844 ↗ |